经济观察网 根据公开信息，美中嘉和（02453.HK）近期有以下动态值得关注： 业务进展情况 2025年12月，公司子公司广州泰和肿瘤医院获准进入粤港澳大湾区"港澳药械通"指定医疗机构名单，这 意味着未来可经审批引进使用港澳已上市但境内尚未获批的肿瘤领域创新药械，可能拓展业务边界并强 化竞争优势。 业绩经营情况 最新财报数据显示，2025年中期公司实现收入约2亿元，亏损同比收窄2.9%，但营收同比减少8.3%。子 公司质子治疗中心投入运营后，医院业务毛利率有所改善，需关注后续盈利能力的持续性。 以上内容基于公开资料整理，不构成投资建议。 高管变动 2026年1月12日，公司宣布姜伟接任总裁职务，这一管理层调整可能影响未来战略执行方向。 ...

2026年2月11日，美中嘉和集团(02453.HK)在国际化战略布局上迈出里程碑式一步。该集团总裁姜伟与 广州泰和肿瘤医院院长钱朝南携核心团队，与印度尼西亚东爪哇省规模最大的综合性医院——泗水国立 医院(National Hospital)正式签署《关于共建综合肿瘤服务中心的合作备忘录》。 • AI智能"点睛"：打破时空界限，激活本地医疗作为本次合作的"点睛之笔"，美中嘉和自主研发的肿瘤 治疗大模型及AI辅助诊疗系统的落地，标志着合作进入了智能化赋能的新阶段。该系统将首先赋能本 地医生，通过大幅提升诊疗效率与精准度，让临床决策更科学。其更深层的价值在于，它将作为桥梁， 通过数字平台开启"跨越国界的医疗协作"新模式——提供远程会诊、第二诊疗意见及MDT多学科讨 论。在此模式下，美中嘉和的专家团队可与印尼医生实时协同，为复杂病例联合制定最优治疗方案，真 正让优质医疗资源突破地域限制，覆盖更广泛的区域。 二、 生态共建：以全周期关怀，铸就有精度更有温度的医疗服务 技术与模式的价值，最终必须以患者获益为依归。因此，本次合作的核心并非单纯的技术输出，而是围 绕"共建肿瘤治疗中心"这一载体，为印尼乃至东南亚构建一个"有 ...

本次合作的核心并非单纯的技术输出，而是围绕"共建肿瘤治疗中心"这一载体，为印尼乃至东南亚构建 一个"有精度、更有温度"的全周期肿瘤医疗服务生态。美中嘉和创新采用"姐妹医院"模式，通过开展深 度的医疗人员交换，派遣资深专家、医学物理师及护理团队赴印尼，进行临床带教与管理赋能，确保国 际水准的诊疗能力在印尼本土实现自我造血与可持续发展。 美中嘉和与印尼顶尖医院的合作，正是美中嘉和"医疗+AI"出海战略的首次系统性实践。以此为全新起 点，美中嘉和的全球化征程将分三步走：第一步，夯实区域据点。以印尼为样板，持续将前沿医疗技术 与AI系统推广至东南亚更多国家，将印尼的成功模式复制并本地化；第二步，构筑核心生态。在各目 标市场打造"医疗技术赋能+AI驱动+跨境转诊"三位一体的核心能力，形成一个既能服务本地患者、又 能联动公司资源的可持续医疗生态；第三步，实现价值共生。通过多元化的服务模式提升长期盈利能 力，降低运营风险，为美中嘉和的中长期稳健增长注入强劲动力，驱动商业价值与社会价值的双重跃 升。 美中嘉和集团总裁姜伟表示："我们将以此次合作为起点，进一步开拓东南亚市场。我们不仅输出技术 与服务，更要传递'以患者为中心'的 ...

2026年2月11日，美中嘉和集团(02453.HK)在国际化战略布局上迈出里程碑式一步。该集团总裁姜伟与 广州泰和肿瘤医院院长钱朝南携核心团队，与印度尼西亚东爪哇省规模最大的综合性医院——泗水国立 医院(National Hospital)正式签署《关于共建综合肿瘤服务中心的合作备忘录》。 此次签约，标志着美中嘉和"医疗+AI"的全球化输出正式启航，不仅是公司全球化战略的关键里程碑， 更是中国高端医疗技术自主创新能力与国际影响力的一次关键跨越。双方将携手在印尼泗水打造一个高 水平的肿瘤诊疗服务平台，致力于为当地民众引入国际标准的医疗服务，并以此为契机，为破解东南亚 普遍面临的肿瘤医疗资源短缺难题，提供一个可借鉴的"印尼模板"。 【深度解读：为何此次合作堪称"破局之举"?】 当前，肿瘤已成为威胁东南亚民众健康的重大挑战。然而，区域内高端医疗资源却严重失衡——尖端设 备稀缺、标准化诊疗体系缺失、AI辅助工具不足，迫使无数患者踏上艰辛的跨境求医路。美中嘉和此 次合作，正是直击这一痛点，以系统性方案引领区域医疗标准升级。 一、 双擎驱动：以"中国智慧"破解全球性医疗难题 美中嘉和深耕肿瘤领域多年，此次带来的不仅是单 ...

2026年2月9日，港股上市公司美中嘉和（02453.HK）旗下广州泰和肿瘤医院一层大堂的揭牌仪式，在 庄重与热烈中定格。当"苏逢锡乳腺肿瘤中心"的红绸落下，这不仅是华南地区乳腺诊疗资源的整合升 级，更是美中嘉和从"设备驱动"向"专科生态"战略升级的关键落子。依托广州泰和肿瘤医院既有的乳腺 专科基础，叠加"国之名医"苏逢锡团队的深度加盟，医院同步整合国际尖端设备资源，一个覆盖预防、 治疗、康复全周期的乳腺肿瘤诊疗平台正式成型，正以"专家+技术+服务"的三重创新，重塑区域医疗 格局。 此次合作的核心价值，在于美中嘉和精准卡位了肿瘤诊疗由顶尖专家团队、尖端诊疗设备、全周期专科 体系共同构成的"黄金三角"。苏逢锡团队深耕乳腺专科40余年，年超千例手术量、58%的保乳率（超行 业均值20个百分点），形成了难以复制的技术壁垒与行业口碑；而广州泰和肿瘤医院作为美中嘉和旗下 三级肿瘤专科医院，其百级层流手术室、ProBeam质子治疗系统、TrueBeam直线加速器等设备，恰好为 专家团队提供了顶尖的硬件支撑，实现了软硬件能力的高度匹配。这种"顶级专家+尖端设备"的组合， 让该中心在乳腺癌治疗领域形成"人无我有"的差异化优势 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 | RMB | | 313,874,624 | | 2. 股份分 ...

Core Viewpoint - The appointment of Jiang Wei as the new president of Meizhong Jiahe Medical Technology Development Group is seen as a significant signal of the company's transition from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem [1][2]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over from Fu Xiao, who retired due to age and organizational adjustments [1]. - Jiang Wei has nearly 20 years of experience in investment banking and capital operations, having previously worked at Ernst & Young and China International Capital Corporation (CICC) before joining Meizhong Jiahe in 2020 [1][2]. Group 2: Strategic Focus - The company aims to integrate its diagnostic capabilities and data resources with AI technology, marking a shift where AI becomes a core driver of the group's strategy [2][3]. - Jiang Wei's leadership is expected to enhance diagnostic efficiency and explore the commercial potential of data assets derived from clinical data [3]. Group 3: Industry Context - The healthcare industry is evolving from a focus on expanding physical infrastructure to improving efficiency and algorithms, indicating a competitive shift [4]. - The appointment of a leader with both capital and technical expertise is anticipated to amplify the company's long-standing capabilities in tumor diagnosis through AI and international expansion strategies [4].

Core Viewpoint - The company announced a leadership change, with Fu Jiao stepping down as president and becoming an advisor, while Jiang Wei will take over as the new president starting January 12, 2026 [1] Group 1 - Fu Jiao will transition to the role of advisor and continue as an executive director after stepping down as president [1] - Jiang Wei, aged 45, has been appointed as the new president and has been with the company since 2020, previously working at Ernst & Young and China International Capital Corporation [1]

Core Viewpoint - The appointment of Jiang Wei as the new CEO of Meizhong Jiahe signals a strategic shift from traditional medical services to an intelligent tumor diagnosis and treatment ecosystem, emphasizing the integration of AI technology into core operations [1][3]. Group 1: Leadership Transition - Jiang Wei, with a strong background in finance and technology, takes over as CEO, indicating a focus on leveraging AI in the healthcare sector [2]. - His previous experience in leading the AI business unit positions him well to drive the company's transformation [2]. Group 2: Strategic Focus on AI - The company aims to integrate AI deeply into its core tumor treatment operations, marking a shift where AI becomes a central driver of strategy rather than a supplementary tool [3]. - The focus will be on enhancing diagnostic capabilities and optimizing clinical pathways through AI [4]. Group 3: Data Asset Utilization - Meizhong Jiahe plans to convert its extensive clinical data into standardized data assets for training more precise AI models, potentially exploring commercial opportunities for data [5]. - The company possesses a unique offline tumor hospital network and vast imaging diagnostic data, which can be leveraged for AI advancements [5]. Group 4: International Expansion - The company is looking to actively expand its overseas business, with standardized medical AI products and high-end tumor treatment services being more conducive to international growth [6]. - Jiang Wei's investment banking background provides a strategic advantage in facilitating technology exports and international capital collaborations [6]. Group 5: Industry Evolution - The healthcare industry is shifting from a focus on acquiring resources to enhancing efficiency and algorithmic capabilities [7]. - Jiang Wei's leadership is expected to amplify the company's long-standing tumor treatment capabilities through AI and international strategies, presenting a new narrative in the capital market [8].

Group 1 - The core announcement is about the leadership change at Meizhong Jiahe (02453.HK), where Fu Xiao will step down as the Group President effective January 12, 2026 [1] - Fu Xiao will transition to a consultant role while continuing to serve as an executive director of the group [1] - Jiang Wei has been appointed as the new President of the group, effective from the same date [1]